Itama Ranoraya (IRRA) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Itama Ranoraya IDR 739, price IDR 360, upside +105.2%, quality 39 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Itama Ranoraya for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 330.00 IDR – 2,168 IDR · fair‑value band 554.11 IDR – 923.51 IDR · the 360.00 IDR price screens below the 738.81 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Itama Ranoraya in your weekly email
Every Wednesday you see whether Itama Ranoraya is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PT Itama Ranoraya Tbk wholesale trades in laboratory and pharmaceutical equipment, and medical devices for humans in Indonesia.
Show more
PT Itama Ranoraya Tbk wholesale trades in laboratory and pharmaceutical equipment, and medical devices for humans in Indonesia. It offers in vitro diagnostics products comprising rapid test, serology, glucose diagnostic, NAPZA test, and clinical laboratory; medical imaging products, including bone densitometer, C-arm, flat panel digital detector, mobile and stationary x-ray, and mammography; nefrology, blood and transfusion, orthopedic, radiotherapy, and surgical products; and hospital supplies and hospital kitchen equipment. The company also provides cold chain management, such as cold room, bloodbank, and pharmaceutical refrigerator; critical care; and pharmaceutical supplements, as well as maternal and neonatal care products. In addition, it leases office space. It sells its products under the oneject, Abbott, Terumo, DIRUI, Medtronic, mindray, ZOLL, Sansin, Vestfrost, ASCENSIA, Hemocue, CUREXO, SATInc., PT. MEGA, Planmed, Sinmed, Balmed, KSM CARE, Trisan Care, Shamrock, OTORO, GEA, Hologic, IS, Avimac, RadmediX, and SMAM brand names. The company was founded in 1988 and is based in Jakarta Timur, Indonesia. PT Itama Ranoraya Tbk operates as a subsidiary of PT Global Dinamika Kencana.
Stock analysis
Itama Ranoraya (IRRA) currently trades at 360.00 IDR, while our model-based Fair Value estimate is 738.81 IDR, implying the stock looks roughly 51.3% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 1,976 IDR per share, and 14 of the 15 models we run sit above the 360.00 IDR price.
Bear case: the Asset-Based group reads lowest at 256.76 IDR, and 1 of the 15 models stay below the price. Evidence for this calculation is low.
Scenario range: 554.11 IDR (bear) to 923.51 IDR (bull), the price of 360.00 IDR sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Itama Ranoraya reported revenue of 1.1T IDR in FY2025 versus 1.3T IDR in FY2021, a compound −4.4%/yr. Reported net income was 65.5B IDR in FY2025, compounding −12.6%/yr from FY2021.
Key figures
Market cap 543B IDR (≈ $30.3M) · P/E ratio 8.5 · P/S ratio 0.50 · EPS (TTM) 42.47 IDR · Net margin 6.0% · Return on equity 11.5% · Return on assets (EBIT) 8.2% · Operating margin 8.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 29% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at 105%, IRRA screens cheaper than that median.
Fair Value models
Bear 554.11 IDRFair Value 738.81 IDRBull 923.51 IDR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (31.18 IDR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+12.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.3%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+63.8%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in IDR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+1.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.3%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.1% vs 58%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 9%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 83 stocks
Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score39 · Bottom 25%
Fair Value upside+105% · Top 25%
Profitability
Return on equity (TTM)11% · Top 25%
Return on assets3% · Above median
Net margin (TTM)6% · Top 25%
Operating margin (TTM)9% · Top 25%
Growth and dividend
Revenue growth−16% · Bottom 25%
Balance sheet
Debt / equity0.43× · Highest 25%
Valuation Multiplesvs Medical Distribution median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Itama Ranoraya Fair Value". https://www.fairvalue-calculator.com/stock/IRRA
Frequently asked questions
Is Itama Ranoraya (IRRA) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 738.81 IDR versus a price of 360.00 IDR, about +105% upside (undervalued).
What is the fair value of IRRA?
Our model-based fair value for Itama Ranoraya is 738.81 IDR (as of Sep 24, 2026), built from audited fundamentals. The current price: 360.00 IDR.
What is the quality score of IRRA?
Itama Ranoraya has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Itama Ranoraya (IRRA)?
Our model-based price target is the fair value of 738.81 IDR (as of Sep 24, 2026) from 15 valuation models. Cautious scenario 554.11 IDR, optimistic scenario 923.51 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Itama Ranoraya stock forecast for 2026?
Our models put fair value at 738.81 IDR, about +105% upside versus a price of 360.00 IDR (undervalued). Cautious scenario 554.11 IDR, optimistic scenario 923.51 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Itama Ranoraya (IRRA)?
Itama Ranoraya reported trailing-twelve-month revenue of about 1.0T IDR (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Itama Ranoraya (IRRA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Itama Ranoraya it is 738.81 IDR per share (as of Sep 24, 2026), against a price of 360.00 IDR. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Itama Ranoraya stock overvalued or undervalued in 2026?
As of Sep 24, 2026, IRRA trades below its calculated fair value: price 360.00 IDR, fair value 738.81 IDR, a gap of about +105% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IRRA?
No. The price is what the market pays today (360.00 IDR); the fair value is what the company's own numbers justify (738.81 IDR). For Itama Ranoraya the two are 378.81 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Itama Ranoraya worth?
The market values Itama Ranoraya at about 543B IDR (market capitalisation, as of Sep 24, 2026). Per share that is 360.00 IDR; our models calculate a fair value of 738.81 IDR per share.
What do the bullish and bearish scenarios say about IRRA?
Our models span a range for Itama Ranoraya: cautious scenario 554.11 IDR, base 738.81 IDR, optimistic 923.51 IDR per share (as of Sep 24, 2026, price 360.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of IRRA?
Itama Ranoraya trades at a price-to-earnings ratio of 8.5 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 738.81 IDR is built from several models across several years. Other multiples: P/B 0.9, P/S 0.5, EV/EBITDA 6.1.
How solid is the balance sheet of Itama Ranoraya (IRRA)?
Balance-sheet figures for Itama Ranoraya (as of Sep 24, 2026): return on equity 11.5%, debt of 0.43 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is IRRA from its 52-week high?
Itama Ranoraya trades at 360.00 IDR, about 29% below its 52-week high of 510.00 IDR and 9% above the low of 330.00 IDR (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 738.81 IDR is for.
Which stocks are comparable to Itama Ranoraya?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Itama Ranoraya stock attractive at the current price?
The data as of Sep 24, 2026: price 360.00 IDR, calculated fair value 738.81 IDR (+105%), Quality Score 39/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IRRA calculated?
We run Itama Ranoraya through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 738.81 IDR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Itama Ranoraya currently trades 105 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Itama Ranoraya (IRRA)?
The closing price on Sep 24, 2026 was 360.00 IDR. Our model-based fair value is 738.81 IDR, about +105% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Itama Ranoraya right now?
The large discount to fair value meets weak quality (39/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (554.11 IDR). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Itama Ranoraya
How large is the market capitalisation of Itama Ranoraya (IRRA)?
The market capitalisation of Itama Ranoraya is 543B IDR (≈ $30.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Itama Ranoraya (IRRA)?
The price-to-sales ratio of Itama Ranoraya is 0.50 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Itama Ranoraya (IRRA)?
Earnings per share at Itama Ranoraya are 42.47 IDR (price ÷ EPS = P/E 8.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Itama Ranoraya (IRRA)?
The net margin of Itama Ranoraya is 6.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Itama Ranoraya (IRRA)?
The return on equity (ROE) of Itama Ranoraya is 11.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Itama Ranoraya (IRRA)?
On an EBIT basis the return on assets of Itama Ranoraya is 8.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Itama Ranoraya (IRRA)?
The operating margin of Itama Ranoraya is 8.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Itama Ranoraya (IRRA)?
Revenue at Itama Ranoraya is growing −15.7% versus a year earlier (3y avg +13.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Itama Ranoraya (IRRA)?
Earnings per share at Itama Ranoraya are growing −1.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Itama Ranoraya (IRRA) generate?
The free cash flow of Itama Ranoraya is −164B IDR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Itama Ranoraya (IRRA) carry?
The net debt of Itama Ranoraya is 756B IDR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Itama Ranoraya in the live analysis
One click puts Itama Ranoraya on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
